X4 Pharmaceuticals (NASDAQ:XFOR) just reported results for the first quarter of 2024.
- X4 Pharmaceuticals reported earnings per share of -26 cents. This was below the analyst estimate for EPS of -16 cents.
- The company did not report any revenue for the quarter.